Key result
The Braile Biomédica bovine pericardial aortic valve prosthesis demonstrated an actuarial survival of 90.59% and freedom from structural dysfunction of 98.57% at 88 months.
Cohort (n=196)
No
Answers are grounded in this paper and cite their sources.
The Braile Biomédica bovine pericardial aortic valve prosthesis demonstrated acceptable mid-to-long-term survival and durability, with 98.57% freedom from structural dysfunction at 88 months.
OBJECTIVE: Aortic valve replacement with Braile bovine pericardial prosthesis has been routinely done at the Heart Institute of the Universidade de São Paulo Medical School since 2006. The objective of this study is to analyze the results of Braile Biomédica® aortic bioprosthesis in patients with aortic valve disease. METHODS: We retrospectively evaluated 196 patients with aortic valve disease submitted to aortic valve replacement with Braile Biomédica® bovine pericardial prosthesis, between 2006 and 2010. Mean age was 59.41±16.34 years and 67.3% were male. Before surgery, 73.4% of patients were in NYHA functional class III or IV. RESULTS: Hospital mortality was 8.16% (16 patients). Linearized rates of mortality, endocarditis, reintervention, and structural dysfunction were 1.065%, 0.91%, 0.68% and 0.075% patients/year, respectively. Actuarial survival was 90.59±2.56% in 88 months. Freedom from reintervention, endocarditis and structural dysfunction was respectively 91.38±2.79%, 89.84±2.92% and 98.57±0.72% in 88 months. CONCLUSION: The Braile Biomédica® pericardial aortic valve prosthesis demonstrated actuarial survival and durability similar to that described in the literature, but further follow up is required to assess the incidence of prosthetic valve endocarditis and structural dysfunction in the future.
No takes yet. Share an insight, caveat, or question.
Azeredo et al. (2014) conducted a cohort in Aortic valve disease (n=196). Braile Biomédica bovine pericardial bioprosthesis was evaluated on Actuarial survival at 88 months. The Braile Biomédica bovine pericardial aortic valve prosthesis demonstrated an actuarial survival of 90.59% and freedom from structural dysfunction of 98.57% at 88 months.
Synapse has enriched 10 related papers. Consider them for comparative context: